Loading...

APC anti-mouse CD86 Antibody APC anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1_APC_090707
LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
  • GL-1_APC_090707
    LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
105011 25 µg DKK571
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105012 100 µg DKK1682
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. D'Avola A, et al. 2022. J Clin Invest. 132: . PubMed
  2. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  3. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  4. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  5. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  6. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  7. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  8. Xu S, et al. 2022. EBioMedicine. 86:104312. PubMed
  9. Liu M, et al. 2022. Cells. 11: . PubMed
  10. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  11. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  12. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  13. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  14. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  15. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  16. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  17. Stoler-Barak L, et al. 2023. Nat Commun. 14:1462. PubMed
  18. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  19. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  20. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  21. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  22. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  23. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  24. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  25. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  26. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  27. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  28. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  29. Arora H, et al. 2019. Immunity. 50:418. PubMed
  30. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  31. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  32. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  33. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  34. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  35. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  36. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  37. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  38. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  39. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  40. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  41. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  42. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  43. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  44. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  45. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  46. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  47. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  48. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  49. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  50. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  51. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  52. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  53. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  54. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  55. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  56. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  57. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  58. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  59. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  60. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  61. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  62. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  63. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  64. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  65. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  66. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  67. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  68. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  69. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  70. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  71. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  72. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  73. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  74. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  75. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  76. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  77. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  78. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  79. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  80. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  81. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  82. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  83. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  84. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  85. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  86. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  87. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  88. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  89. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  90. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  91. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  92. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  93. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  94. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  95. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  96. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  97. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  98. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  99. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  100. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  101. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  102. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  103. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  104. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  105. D'Avola A, et al. 2022. J Clin Invest. 132: . PubMed
  106. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  107. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  108. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  109. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  110. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  111. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  112. Xu S, et al. 2022. EBioMedicine. 86:104312. PubMed
  113. Liu M, et al. 2022. Cells. 11: . PubMed
  114. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  115. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  116. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  117. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  118. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  119. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  120. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  121. Stoler-Barak L, et al. 2023. Nat Commun. 14:1462. PubMed
  122. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  123. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  124. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  125. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  126. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  127. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  128. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  129. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  130. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  131. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  132. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  133. Arora H, et al. 2019. Immunity. 50:418. PubMed
  134. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  135. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  136. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  137. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  138. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  139. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  140. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  141. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  142. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  143. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  144. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  145. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  146. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  147. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  148. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  149. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  150. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  151. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  152. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  153. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  154. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  155. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  156. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  157. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  158. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  159. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  160. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  161. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  162. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  163. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  164. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  165. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  166. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  167. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  168. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  169. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  170. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  171. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  172. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  173. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  174. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  175. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  176. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  177. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  178. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  179. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  180. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  181. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  182. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  183. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  184. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  185. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  186. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  187. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  188. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  189. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  190. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  191. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  192. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  193. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  194. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  195. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  196. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  197. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  198. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  199. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  200. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  201. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  202. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  203. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  204. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  205. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  206. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  207. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  208. Trivedi S, et al. 2020. Elife. 9:00. PubMed
RRID
AB_493343 (BioLegend Cat. No. 105011)
AB_493342 (BioLegend Cat. No. 105012)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1_APC_090707
LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
  • GL-1_APC_090707
    LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
105011 25 µg DKK571
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105012 100 µg DKK1682
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. D'Avola A, et al. 2022. J Clin Invest. 132: . PubMed
  2. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  3. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  4. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  5. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  6. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  7. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  8. Xu S, et al. 2022. EBioMedicine. 86:104312. PubMed
  9. Liu M, et al. 2022. Cells. 11: . PubMed
  10. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  11. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  12. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  13. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  14. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  15. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  16. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  17. Stoler-Barak L, et al. 2023. Nat Commun. 14:1462. PubMed
  18. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  19. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  20. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  21. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  22. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  23. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  24. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  25. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  26. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  27. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  28. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  29. Arora H, et al. 2019. Immunity. 50:418. PubMed
  30. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  31. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  32. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  33. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  34. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  35. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  36. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  37. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  38. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  39. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  40. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  41. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  42. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  43. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  44. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  45. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  46. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  47. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  48. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  49. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  50. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  51. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  52. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  53. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  54. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  55. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  56. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  57. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  58. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  59. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  60. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  61. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  62. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  63. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  64. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  65. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  66. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  67. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  68. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  69. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  70. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  71. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  72. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  73. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  74. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  75. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  76. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  77. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  78. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  79. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  80. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  81. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  82. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  83. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  84. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  85. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  86. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  87. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  88. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  89. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  90. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  91. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  92. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  93. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  94. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  95. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  96. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  97. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  98. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  99. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  100. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  101. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  102. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  103. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  104. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  105. D'Avola A, et al. 2022. J Clin Invest. 132: . PubMed
  106. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  107. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  108. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  109. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  110. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  111. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  112. Xu S, et al. 2022. EBioMedicine. 86:104312. PubMed
  113. Liu M, et al. 2022. Cells. 11: . PubMed
  114. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  115. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  116. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  117. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  118. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  119. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  120. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  121. Stoler-Barak L, et al. 2023. Nat Commun. 14:1462. PubMed
  122. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  123. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  124. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  125. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  126. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  127. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  128. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  129. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  130. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  131. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  132. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  133. Arora H, et al. 2019. Immunity. 50:418. PubMed
  134. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  135. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  136. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  137. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  138. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  139. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  140. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  141. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  142. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  143. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  144. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  145. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  146. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  147. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  148. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  149. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  150. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  151. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  152. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  153. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  154. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  155. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  156. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  157. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  158. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  159. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  160. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  161. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  162. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  163. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  164. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  165. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  166. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  167. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  168. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  169. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  170. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  171. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  172. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  173. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  174. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  175. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  176. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  177. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  178. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  179. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  180. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  181. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  182. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  183. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  184. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  185. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  186. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  187. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  188. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  189. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  190. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  191. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  192. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  193. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  194. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  195. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  196. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  197. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  198. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  199. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  200. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  201. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  202. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  203. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  204. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  205. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  206. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  207. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  208. Trivedi S, et al. 2020. Elife. 9:00. PubMed
RRID
AB_493343 (BioLegend Cat. No. 105011)
AB_493342 (BioLegend Cat. No. 105012)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account